Collinsella Aerofaciens Test · Stool

Your gut is home to trillions of bacteria, and a few of them keep showing up in research on fatty liver, obesity, insulin resistance, heart disease, and inflammatory conditions. Collinsella aerofaciens is one of those names. When its numbers drift too high, it tends to track with metabolic dysfunction and a leakier, more inflamed gut. When its numbers drift too low, it has shown up in conditions like depression and diabetic nerve damage.

This test looks at how much of this specific bacterium lives in your stool. It is a research oriented marker, not a diagnosis, but it can open a window into how your diet, metabolism, and gut lining are interacting. Tracked over time, it can also hint at whether a fiber change, a probiotic, or a lifestyle shift is actually moving your internal biology.

What Collinsella aerofaciens Actually Is

Collinsella aerofaciens (C. aerofaciens for short) is a bacterial species, not a hormone or a metabolite. It belongs to a family of bacteria that ferment carbohydrates in your colon and help shape how you digest fiber, handle bile acids, and regulate the protective lining of your gut. Some of its products support a healthy gut barrier, while others, under the wrong conditions, appear to stoke inflammation.

In research, this bacterium is usually measured by reading the DNA sequence of the bacteria in a stool sample (a technique called 16S rRNA sequencing) or by using a species specific DNA amplification test (qPCR). What you get back is an abundance estimate, meaning how much of your total gut bacterial population belongs to this species.

Fatty Liver Disease and NASH

The clearest metabolic association for this bacterium is with non alcoholic fatty liver disease (NAFLD) and its more advanced form, non alcoholic steatohepatitis (NASH), where fat buildup in the liver progresses to inflammation and scarring. Biopsy confirmed NASH patients have been found to carry a higher abundance of the broader Collinsella group compared with healthy people, alongside lower overall bacterial diversity.

Laboratory work on strains isolated from NASH patients shows genomes enriched for carbohydrate metabolism and fat building pathways. In follow up animal work, introducing this bacterium raised blood ethanol (alcohol your own gut bacteria produce) and worsened liver inflammation. These mechanistic findings suggest a plausible role in how fatty liver progresses, but human data remain cross sectional rather than proof that the bacterium causes the disease.

Obesity, Insulin Resistance, and Type 2 Diabetes

Higher abundance of this bacterium has repeatedly shown up in people who are overweight or obese, and in those with type 2 diabetes. In a large Asian population study, C. aerofaciens was enriched in one microbial pattern linked to type 2 diabetes and altered glucose and energy metabolism.

Pregnancy research points in the same direction. In overweight and obese pregnant women, higher Collinsella abundance tracked with higher insulin levels and lower dietary fiber intake. Eating a low fiber diet appears to favor this bacterium's growth, which in turn appears to push metabolism in a less healthy direction.

Heart Disease and Blood Pressure

In a population based study of over 3,500 adults, this bacterium was associated with the severity of nighttime low oxygen episodes from obstructive sleep apnea (OSA) and with higher blood pressure. Separate microbiome work in people with coronary artery disease and cardiac valve calcification has flagged Collinsella as a central node in the bacterial networks that differ between cardiac patients and healthy controls.

Immune and Autoimmune Conditions

Collinsella is enriched in people with rheumatoid arthritis, including those with rheumatoid arthritis associated interstitial lung disease, where it appears in a dysbiotic pattern that some researchers consider a candidate biomarker. In a study of autoimmune polyendocrine syndrome type 1, a three month probiotic intervention reduced Collinsella abundance alongside improvement in gastrointestinal symptoms.

Brain, Mood, and Nerve Health

A large genetic analysis found that a genetically higher abundance of the Collinsella genus is a risk factor for Alzheimer's disease and correlates with APOE risk alleles, consistent with a pro inflammatory, lipid related role. A systematic review of human microbiome to brain connectivity studies has repeatedly flagged Collinsella among the genera linked to measurable brain network differences.

The picture in mood and nerve disorders is more complex. Adolescents with major depressive disorder showed lower Collinsella abundance than healthy peers, and that reduction tracked with markers of a more permeable gut and more systemic inflammation. People with diabetic peripheral neuropathy also had lower Collinsella than people with diabetes who had not developed nerve damage.

Why This Bacterium Can Look Good or Bad

One question the data raises is how the same bacterium can be enriched in NAFLD, obesity, and rheumatoid arthritis, but depleted in depression and nerve damage. The cleanest way to resolve this is to stop thinking of Collinsella aerofaciens as a simple good bug or bad bug. Its effects appear to depend heavily on context, including how much fiber you eat, the state of your gut lining, and the rest of your microbial community. Levels that look protective in one setting can behave like pathobionts (harmful commensals) in another. That is why a single result, without context from diet, symptoms, and other labs, is rarely enough to act on.

Reference Ranges

There are no clinically standardized reference ranges or cutpoints for Collinsella aerofaciens. No guideline body has defined a normal or optimal abundance, and different labs use different sequencing methods, databases, and normalization approaches, which can produce meaningfully different numbers for the same sample. Anything labeled optimal on a report is analytical orientation based on the lab's own reference population, not a validated target.

What this means for you: compare your results within the same lab over time, rather than against a universal cutpoint. The direction and size of change in your own numbers is more informative than any single snapshot.

Tracking Your Trend

For a research grade microbiome marker like this one, a single reading is a starting point, not a verdict. Gut bacterial abundances can shift within days in response to diet, stress, illness, or antibiotics, and trial data show this bacterium can be deliberately moved with targeted interventions over weeks. What you want is a trajectory, not one data point.

A reasonable cadence is to get a baseline, retest in 3 to 6 months if you are making meaningful dietary or lifestyle changes, and then at least annually after that. Keep the same lab across tests whenever possible so you are comparing apples to apples.

When Results Can Be Misleading

Several short term factors can distort a single reading and should be noted when you sample:

• Recent acute stressors: strenuous exercise, heat, cold, high altitude, sleep restriction, and psychological stress can all shift gut bacterial composition within days. A 4 day intensive Arctic military training exercise shifted more than half of observed bacterial genera, including Collinsella, before levels began returning toward baseline.
• Antibiotics and acute infections: these can cause large, usually temporary drops in diversity and shifts in specific taxa, with recovery taking weeks.
• Abrupt diet changes: sudden jumps or drops in fiber, fat, carbohydrate, or protein intake in the days before testing can move the numbers in ways that do not reflect your usual gut ecology.
• Method and lab variability: different sequencing platforms, primers, and reference databases can produce different abundance estimates from the same stool, which is why within lab trending matters more than cross lab comparisons.

What to Do With an Abnormal Result

Because this is an exploratory marker without standardized cutpoints, an unusual result should prompt investigation, not panic. If your abundance is markedly high alongside known cardiometabolic risk signals, it is worth looking at liver enzymes (ALT, AST, GGT), lipids including ApoB, fasting insulin, and HbA1c to see whether a metabolic pattern is emerging. If symptoms point toward irritable bowel syndrome, inflammation, or autoimmune disease, a broader stool panel covering inflammation markers, digestive function, and overall microbial balance will give more actionable context than this single species. A gastroenterologist, hepatologist, or functional medicine clinician who works regularly with microbiome data can help integrate the result with your clinical picture.